Enesi Pharma’s ImplaVax® platform nominated for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020

OXFORD, UK – 4 February 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been nominated in the Best New Vaccine Technology/Platform category, at the 13th Annual Vaccine Industry Excellence (ViE) Awards. The ViE Awards honour and recognize the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress, taking place on 6-9 April in Washington, DC.

For the past 19 years, the World Vaccine Congress Washington has evolved and grown into the leading vaccines congress globally, with over 300 speakers and 1,500 attendees. The event is a leading forum for discussing how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce and deliver more and better vaccines to the market.

David Hipkiss, Enesi CEO said

“We are very pleased to have been nominated in the Best New Vaccine Technology/Platform category at such a prestigious global event, this recognising the Enesi Team’s outstanding efforts in applying and leveraging our unique needle-free, unit sold dose, ImplaVax® vaccination technology across several targets and which are set to make a material impact on global health.”